Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2012

Abingdon Health Raises £3M to Buy 50.1% of POC Dx Firm Molecular Vision

  • U.K.-based diagnostics firm Abingdon Health received a £2 million (about $3.2 million) equity investment from Imperial Innovations Group, and another £1.02 million from private investors, to fund its acquisition of a 50.1% interest in Imperial’s portfolio company Molecular Vision. Imperial Innovations invests in technologies originating from Imperial College London, Cambridge University, Oxford University, and University College London. Following the investment round, Imperial Innovations will hold a 28.6% stake in Abingdon Health and retain a 36.4% stake in Molecular Vision.

    Abingdon says the £3 million fundraising will also allow it to invest in other projects, including portfolio companies established by Bioscience Ventures, a joint venture between Abingdon and the University of Birmingham.  

    Molecular Vision is developing a disposable, quantitative point-of-care diagnostic device called BioLED, which is designed to test simultaneously for multiple disease markers. The optical detection platform combines lab-on-a-chip and light-emitting polymer LEP technologies. To date, the development focus has been for diagnostic applications in kidney function and cardiovascular disease, but Abingdon maintains the platform technology could be used for in a wide range of fields including biodefense.

    Abingdon’s Bioscience Ventures initiative with the University of Birmingham was launched in 2010 to develop and commercialize university IP into diagnostic tools and platform technologies. The current portfolio of companies includes: Serascience, which is developing point-of-care tests for diagnosing myeloma and related conditions; Linear Diagnostics, which is developing a linear dichroism-based platform for the multiplexed detection of infectious disease agents in sepsis; and Alta Bioscience, which specializes in the manufacture of peptides and oligos, and offers amino acid analysis and protein sequencing services. Bioscience Ventures is separately developing a urine-based test for diagnosing adrenal cancer. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »